Records containing: Primary Hyperoxaluria

This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.

• CLINICAL_TRIALS study record update · 2026-04-16
  A Phase 2 Open-Label Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nedosiran in Pediatric Patients From Birth to 11Years of Age With Primary Hyperoxaluria and Relatively Intact Renal Function
• CLINICAL_TRIALS study record update · 2025-08-12
  Universal Genomic Newborn Screening in the Wallonia-Brussels Federation: Baby Detect
• CLINICAL_TRIALS study record update · 2025-07-22
  Rare Kidney Stone Consortium Biobank, Rare Diseases Clinical Research Network
• CLINICAL_TRIALS study record update · 2025-07-04
  Rare Kidney Stone Consortium Registry for Hereditary Kidney Stone Diseases
• CLINICAL_TRIALS study record update · 2024-09-19
  A Placebo-Controlled, Single-Blind, Single-Center Phase 1 Study in Normal Healthy Volunteers and Open-Label Multi-Center Study in Patients With Primary Hyperoxaluria to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of DCR-PHXC Solution for Injection (Subcutaneous Use)
• Organize your saved records without ads with Plus.
• CLINICAL_TRIALS study record update · 2024-04-25
  A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Administration of ALN-GO1 in Patients With Primary Hyperoxaluria Type 1
• CLINICAL_TRIALS study record update · 2024-02-16
  Expanded Access Protocol to Provide Lumasiran to Patients With Primary Hyperoxaluria Type 1
• CLINICAL_TRIALS study record update · 2023-10-04
  National Registry of Rare Kidney Diseases (RaDaR)
• CLINICAL_TRIALS study record update · 2023-05-06
  Scientific Basis for a Newborn Screening for Cystinosis and Primary Hyperoxaluria
• CLINICAL_TRIALS study record update · 2022-09-02
  Assessment of Health-related Quality of Life in Rare Kidney Stone Formers in the Rare Kidney Stone Consortium
• CLINICAL_TRIALS study record update · 2022-07-12
  ILLUMINATE-C: A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1 (PH1)
• CLINICAL_TRIALS study record update · 2021-12-09
  A Phase 2 Open-label Multi-centre Study to Evaluate the Efficacy and Safety of Oxabact® to Reduce Plasma Oxalate in Subjects With Primary Hyperoxaluria Who Are on Dialysis
• CLINICAL_TRIALS study record update · 2021-12-09
  A Phase III Double-blind, Randomised Study to Evaluate the Long-term Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria
• CLINICAL_TRIALS study record update · 2021-11-04
  Phenotyping of Primary Hyperoxaluria in Children and Adults
• CLINICAL_TRIALS study record update · 2021-07-19
  ILLUMINATE-B: An Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1
• CLINICAL_TRIALS study record update · 2021-03-26
  Evaluation of the Efficacy of Stiripentol (Diacomit) as Monotherapy for the Treatment of Primary Hyperoxaluria
• CLINICAL_TRIALS study record update · 2020-12-30
  Pilot Study of ALLN-177 in Adult and Pediatric Subjects Aged 12 Years or Older With Enteric or Primary Hyperoxaluria and Hyperoxalemia
• CLINICAL_TRIALS study record update · 2019-08-19
  Genetic Characterization and Genotype/Phenotype Correlations in Primary Hyperoxaluria
• CLINICAL_TRIALS study record update · 2016-07-07
  Correlation of Disease Expression With Specific Genetic Mutations in Primary Hyperoxaluria
• CLINICAL_TRIALS study record update · 2015-10-16
  A Phase 1/2, Randomised, Placebo-controlled, Double-blind, Multi-centre Study to Evaluate the Efficacy and Safety of OC5 to Reduce Urinary Oxalate in Subjects With Primary Hyperoxaluria
• CLINICAL_TRIALS study record update · 2015-04-07
  International Registry for Hereditary Calcium Stone Diseases
• CLINICAL_TRIALS study record update · 2013-05-15
  A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multi-center, International Study to Evaluate the Efficacy and Safety of OxabactTM to Reduce Urinary Oxalate in Subjects With Primary Hyperoxaluria
• CLINICAL_TRIALS study record update · 2013-05-15
  A Phase 2/3, Double-blind, Randomized, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of OxabactTM to Reduce Urinary Oxalate in Subjects With Primary Hyperoxaluria.